Adoption of an Anti vaccine CO VID-19 is near, however, still has unanswered questions

However, this is only an initial assessment. The performance data within specific demographic groups is not yet available. Leif Erik Sander of the Charite Hospital in Berlin says the level of effectiveness for people belonging to high-risk groups has not been determined yet.

The 90 percent claim of efficiency is not yet published in a medical journal, says Sander. If the claim is proven, it will be an extremely high percentage of efficiency, he adds.

The European Commission has negotiated with Pfizer and BioNTech for months to get the vaccine to EU members as soon as it becomes available. German Health Minister Jens Spahn said Berlin had sought about 100 million doses of vaccines. EU members will receive doses in line with their population.

Who wants the dosage first? Older people, especially those with acute diseases and health professionals, will take priority in distributing vaccines. People who do the necessary jobs for the functioning of society including government officials, police officers, firefighters and teachers will also have an advantage.

According to Spahn, the vaccine will take place at the designated centres for what will be placed in Germany in the next 10 days. Mobile medical teams will also undergo vaccines. Marketing and storage of vaccines can be challenging in view of the fact that the vaccine must be held at -70 degrees Celsius.

There is no possibility that a single dose of the coronary vaccine can make a life receiver immune. Experts say the vaccine will have to be repeated, similar to the flu. The big question without answer is whether someone who is immune to the vaccine can still transmit the virus to others. This could be a big problem in the case of health professionals.